Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HLA Class II Protein Expression Regulation Is Strongly Linked to Cis-Acting SNPs.

HLA·2026
Same author

PFA-100 System: A New Method for Assessment of Platelet Dysfunction.

Seminars in thrombosis and hemostasis·2023
Same author

Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: facilitating research through infrastructure, workforce, resources and funding.

Expert review of hematology·2023
Same author

The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development.

Blood advances·2020
Same author

Non-Compartment and compartmental pharmacokinetics, efficacy, and safety of Kedrion FIX concentrate.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2020
Same author

Author Correction: CCR5AS lncRNA variation differentially regulates CCR5, influencing HIV disease outcome.

Nature immunology·2019
Same journal

Real-World Outcomes of Prophylaxis With rIX-FP in Germany: A Prospective, Non-Interventional Study in Haemophilia B.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Prophylactic Factor Replacement Versus on-Demand Factor Replacement Following Primary Total Knee Arthroplasty in Patients With Hemophilia: A Retrospective Study With an Average 10-Year Follow-up.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Accuracy of Factor VIII Assays for Measuring Damoctocog Alfa Pegol: A Comparative Analysis.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Real-World Assessment of rVIII-SingleChain for Prophylactic Treatment in People With Severe Hemophilia A in High-Resource Settings.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Platelet Hyperreactivity May Contribute to Thrombotic Complications in Afibrinogenemia: A Case-Based Observation.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Predictors and Clinical Impact of Time to Diagnosis in Acquired Haemophilia A: An 11-Year Retrospective Cohort Study.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
See all related articles

Related Experiment Video

Updated: Jun 11, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Clinical issues in inhibitors.

J Astermark1, E Santagostino, W Keith Hoots

  • 1Centre for Thrombosis and Haemostasis, Skane University Hospital, Malmö, Sweden.

Haemophilia : the Official Journal of the World Federation of Hemophilia
|July 2, 2010
PubMed
Summary
This summary is machine-generated.

Anamestic inhibitors complicate hemophilia therapy, often requiring bypassing agents when factor replacement fails. Immune tolerance induction and bypassing agent prophylaxis are strategies to manage inhibitor-related morbidity.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Experiment Videos

Last Updated: Jun 11, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Area of Science:

  • Hematology
  • Immunology
  • Internal Medicine

Background:

  • Anamestic inhibitors are a significant complication in hemophilia therapy.
  • Current clotting factor concentrates minimize pathogen transmission risks.
  • Conventional factor replacement is often inadequate for patients with high-responding inhibitors.

Purpose of the Study:

  • To review strategies for managing hemophilia patients with anamestic inhibitors.
  • To discuss the efficacy and risks of bypassing agents and immune tolerance induction.
  • To explore the emerging use of bypassing agents in prophylaxis.

Main Methods:

  • Literature review of treatment strategies for hemophilia inhibitors.
  • Analysis of the benefits and risks associated with current therapeutic approaches.
  • Discussion of immune tolerance induction and bypassing agent use.

Main Results:

  • Bypassing agents are necessary for bleeding management in many inhibitor patients but offer variable hemostasis.
  • Immune tolerance induction has variable success rates, leaving many patients with persistent inhibitors and high morbidity.
  • Prophylactic use of bypassing agents is being explored to reduce morbidity.

Conclusions:

  • Managing hemophilia patients with anamestic inhibitors remains challenging.
  • Existing strategies like bypassing agents and immune tolerance induction have limitations.
  • Further research and clinical strategies are needed to improve outcomes for these patients.